Search

Your search keyword '"HEVELONE, NATHANAEL D."' showing total 76 results
Start Over Author "HEVELONE, NATHANAEL D."
76 results on '"HEVELONE, NATHANAEL D."'

57. Cost Analysis of Face Transplantation

Author

Nguyen, Louis L., primary, Naunheim, Matthew R., additional, Hevelone, Nathanael D., additional, Diaz-Siso, Jesus R., additional, Hogan, John P., additional, Bueno, Ericka M., additional, and Pomahac, Bohdan, additional

Published
2012
Full Text
View/download PDF

66. The Impact of Prostate Size, Median Lobe, and Prior Benign Prostatic Hyperplasia Intervention on Robot-Assisted Laparoscopic Prostatectomy: Technique and Outcomes

Author

Huang, Andy C., primary, Kowalczyk, Keith J., additional, Hevelone, Nathanael D., additional, Lipsitz, Stuart R., additional, Yu, Hua-yin, additional, Plaster, Blakely A., additional, Amarasekara, Channa A., additional, Ulmer, William D., additional, Lei, Yin, additional, Williams, Stephen B., additional, and Hu, Jim C., additional

Published
2011
Full Text
View/download PDF

70. Preoperative Electrocardiograms

Author

Correll, Darin J., primary, Hepner, David L., additional, Chang, Candace, additional, Tsen, Lawrence, additional, Hevelone, Nathanael D., additional, and Bader, Angela M., additional

Published
2009
Full Text
View/download PDF

75. Craniofacial Measurements of Donors and Recipients Correlate with Aesthetic Outcome in Virtual Face Transplantation.

Author

Wallins JS, Chandawarkar AA, Dobry A, Diaz-Siso JR, Bueno EM, Caterson EJ, Jania C, Hevelone ND, Lipsitz SR, Mukundan S Jr, and Pomahac B

Abstract

Background: Face transplantation is an increasingly feasible option for patients with severe disfigurement. Donors and recipients are currently matched based on immune compatibility, skin characteristics, age, and gender. Aesthetic outcomes of the match are not always optimal and not possible to study in actual cases due to ethical and logistical challenges. We have used a reproducible and inexpensive three-dimensional virtual face transplantation (VFT) model to study this issue., Methods: Sixty-one VFTs were performed using reconstructed high-resolution computed tomography angiographs of male and female subjects aged 20-69 years. Twenty independent reviewers evaluated the level of disfigurement of the posttransplant models. Absolute differences in 9 soft-tissue measurements and 16 bony cephalometric measurements from each of the VFT donor and recipient pretransplant model pairs were correlated to the reviewers' evaluation of disfigurement after VFT through a multivariate logistic regression model., Results: Five soft-tissue measurements and 3 bony measurements were predictive of the rating of disfigurement after VFT (odds ratio; 95% confidence interval): trichion-to-nasion facial height (1.106; 1.066-1.148), endocanthal width (1.096; 1.051-1.142), exocanthal width (1.067; 1.036-1.099), mouth/chelion width (1.064; 1.019-1.110), subnasale-to-menton facial height (1.029; 1.003-1.056), inner orbit width (1.039; 1.009-1.069), palatal plane/occlusal plane angle (1.148; 1.047-1.258), and sella-nasion/mandibular plane angle (1.079; 1.013-1.150)., Conclusions: This study provides early evidence for the importance of soft-tissue and bony measurements in planning of facial transplantation. With future improvements to immunosuppressive regimens and increased donor availability, these measurements may be used as an additional criterion to optimize posttransplant outcomes.

Published
2015
Full Text
View/download PDF

76. Provision of a soy-based intravenous lipid emulsion at 1 g/kg/d does not prevent cholestasis in neonates.

Author

Nehra D, Fallon EM, Carlson SJ, Potemkin AK, Hevelone ND, Mitchell PD, Gura KM, and Puder M

Subjects
Bilirubin blood, Cholestasis blood, Cholestasis etiology, Enteral Nutrition, Female, Fish Oils administration & dosage, Humans, Infant, Newborn, Male, Parenteral Nutrition methods, Retrospective Studies, Cholestasis prevention & control, Fat Emulsions, Intravenous administration & dosage, Fat Emulsions, Intravenous adverse effects, Parenteral Nutrition adverse effects, Soybean Oil administration & dosage, Soybean Oil adverse effects
Abstract

Background: One of the most common and severe complications of long-term parenteral nutrition (PN) is PN-associated cholestasis. The soybean oil-based lipid emulsion administered with PN has been associated with cholestasis, leading to an interest in lipid reduction strategies. The purpose of this study was to determine whether the provision of a soybean oil-based lipid emulsion at 1 g/kg/d compared with 2-3 g/kg/d is associated with a reduced incidence of cholestasis., Methods: Retrospective review of neonates admitted between 2007 and 2011 with a gastrointestinal condition necessitating ≥ 21 days of PN support. Neonates were divided into 2 groups based on the intravenous lipid emulsion dose: 1-g group (1 g/kg/d) and 2- to 3-g group (2-3 g/kg/d). The primary outcome measure was the incidence of cholestasis., Results: Sixty-one patients met inclusion criteria (n = 29, 1-g group; n = 32, 2- to 3-g group). The 2 groups did not differ in any baseline characteristics other than associated comorbidities that were more common in the 2- to 3-g group. The duration of PN, the number of operative procedures and bloodstream infections, and enteral nutrition (EN) were similar between groups. The incidence of cholestasis was not different between groups (51.7%, 1-g group; 43.8%, 2- to 3-g group; P = .61), and there was no difference between groups in the time to cholestasis (32.6 ± 24.1 days, 1-g group; 27.7 ± 10.6 days, 2- to 3-g group; P = .48). Overall, 44.8% of patients with cholestasis were transitioned to full EN, and 55.2% were transitioned to a fish oil-based lipid emulsion after which the direct bilirubin normalized in all patients., Conclusion: Lipid reduction to 1 g/kg/d does not prevent or delay the onset of cholestasis in neonates.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results